esophageal squamous cell carcinoma (escc)
Showing 1 - 8 of 8
Esophageal Squamous Cell Carcinoma (ESCC), PD-1 Inhibitors Trial in Zhengzhou (IBI110+Sintilimab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- PD-1 Inhibitors
-
Zhengzhou, Henan, ChinaFeng Wang
Oct 9, 2023
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC) Trial in
Recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- +2 more
- pembrolizumab
- +7 more
-
Long Beach, California
- +158 more
Jan 19, 2023
Esophageal Squamous Cell Carcinoma (ESCC) Trial in Japan, Taiwan (Pembrolizumab, Coformulation favezelimab/pembrolizumab,
Recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- Pembrolizumab
- +5 more
-
Milan, Lombardia, Italy
- +13 more
Jan 3, 2023
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
Not yet recruiting
- Locally Advanced or Metastatic Solid Tumors
- +3 more
- (no location specified)
Jul 24, 2022
Esophageal Squamous Cell Carcinoma (ESCC) Trial in Worldwide (Cisplatin, Oxaliplatin, Fluorouracil (5-FU))
Active, not recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- Cisplatin
- +6 more
-
New Haven, Connecticut
- +160 more
Apr 26, 2022
Esophageal Squamous Cell Carcinoma (ESCC) Trial in China (Tislelizumab, Placebo, Paclitaxel)
Active, not recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- Tislelizumab
- +4 more
-
Beijing, Beijing, China
- +31 more
Mar 1, 2022
Esophageal Squamous Cell Carcinoma (ESCC) Trial in Worldwide (Tislelizumab, Paclitaxel, Docetaxel)
Active, not recruiting
- Esophageal Squamous Cell Carcinoma (ESCC)
- Tislelizumab
- +3 more
-
Fullerton, California
- +131 more
Nov 23, 2021
Esophageal Squamous Cell Carcinoma (ESCC) Trial in Taiwan (BI-754091 plus afatinib)
Enrolling by invitation
- Esophageal Squamous Cell Carcinoma (ESCC)
- BI-754091 plus afatinib
-
Kaohsiung, Taiwan
- +4 more
Aug 30, 2021